Precision Biologics, a NantWorks Company, to Present Combination Immunotherapy of Novel Neo-Epitope Anitbody Targeting Ovarian and Uterine Cancer at the AACR Annual Meeting 2016

Positive preclinical data on a novel human monoclonal antibody that specifically targets ovarian and uterine cancer subtypes and demonstration of augmented tumor killing with high affinity CD16 Natural Killer cells as combination therapy

Culver City, CA and New Orleans – April 17, 2016 —Precision Biologics, a NantWorks affiliated clinical stage biotechnology company focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer and a participant in the Cancer Breakthroughs 2020, today announced it will present a poster titled, “Identification of target and cytotoxicity of novel monoclonal antibody NEO-201 in ovarian and uterine cancer subtypes” at the American Association for Cancer Research (AACR) Annual Meeting 2016.